Genmab A/S (GMAB) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Genmab A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.715 Hello and welcome to the GENMAP first half 2026 financial results conference call. 00:00:05.715 -- 00:00:09.138 As a reminder, this conference call is being recorded. 00:00:09.138 -- 00:00:13.121 During this telephone conference, you may be presented with forward-looking statements 00:00:13.121 -- 00:00:18.105 that include words such as beliefs, anticipates, plans or expects. 00:00:18.105 -- 00:00:22.568 Actual results may differ materially, for example, as a result of delayed or unsuccessful 00:00:22.568 -- 00:00:27.772 development projects. GENMAP is not under any obligation to update statements 00:00:27.772 -- 00:00:32.596 regarding the future, and many more. We encourage you to review our full financial statements 00:00:32.596 -- 00:00:35.356 and publicly filed reports 00:00:56.757 -- 00:00:59.959 and not to rely on any single financial measure. 00:00:59.959 -- 00:01:05.101 Please also note that GENMAP may hold your personal data as indicated by you as a part 00:01:05.101 -- 00:01:10.264 of our investor relations outreach activities in order to update you on GENMAP going 00:01:10.264 -- 00:01:15.386 forward. Please refer to our website for more information on GENMAP and our privacy 00:01:15.386 -- 00:01:17.207 policy. 00:01:17.207 -- 00:01:21.009 I would like to hand the conference over to our first speaker today, Jan van de Winkel. 00:01:21.009 -- 00:01:23.174 Please go ahead. 00:01:23.174 -- 00:01:28.979 Hello, everyone, and welcome to our financial results call for the first half of 2026. 00:01:28.979 -- 00:01:33.762 With me today is our Chief Financial Officer, Anthony Pagano, our Chief Commercial Officer, 00:01:33.762 -- 00:01:38.046 Brad Bailey, and our Chief Medical Officer, Tahy Ahmadi. 00:01:38.046 -- 00:01:43.508 For ...